Cytokinetics (CYTK) investor relations material

Strategic priorities and business outlook

• Focused on expanding MYQORZO's label and market presence through 2027, with strong early commercial momentum in the U.S., China, and Europe.

• Strategic investments supported by $1.8 billion in financial resources, enabling further R&D and global expansion.

• Vision 2030 includes direct launches in major markets and partnerships in regions like Japan and China.

• Emphasis on maintaining leadership and innovation in the cardiac myosin inhibitor (CMI) space.

Product launches and commercial performance

• MYQORZO launched successfully in the U.S., China, and Europe, with rapid uptake and positive prescriber feedback.

• Early sales show 20% of prescribers are new to CMIs, indicating market expansion beyond established centers.

• Majority of Q1 prescriptions are new to brand, with some switches from CAMZYOS.

• Targeting majority share of new prescriptions by year-end, with parity Medicare access expected by mid-year and commercial parity by year-end.

Clinical data and regulatory updates

• Positive results from ACACIA-HCM support potential label expansion to non-obstructive HCM, with data described as transformative.

• MAPLE-HCM data challenged beta blockers as first-line therapy, driving enthusiasm for earlier CMI use.

• sNDA for MAPLE data under FDA review with a PDUFA date in November; ACACIA sNDA expected.

• Label and guideline updates anticipated to accelerate frontline adoption and payer acceptance.